Tilburg

• A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc … Unknown
  2022-502779-40-99 5 Primary prevention of atherosclerotic cardiovascular disease (ASCVD)
• A clinical study of MK-7240 for the treatment of ulcerative colitis (MK-7240-001) Unknown
  2025-523766-25-00 5 Ulcerative colitis
• Avelumab Short Maintenance Trial Pending
  2024-512975-11-01 11 urothelial cancer
• ATLAS trial Pending
  2024-517233-40-00 6 Perianal abscess
• A trial to learn how well sonesitatug vedotin and capecitabine with or without rilvegostomig work and how safe they are in adults with cance … Pending
  2024-519787-40-00 5 Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal C
• A maintenance study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn’s disease Pending
  2025-521037-86-00 5 Immune system diseases
• Adjuvant Pembrolizumab in patients with early-stage triple negative breast cancer with residual disease after treatment with chemotherapy an … Pending
  2025-524229-41-00 5 Triple negative breast cancer
• HO182 CLL: Treatment of patients with chronic lymphocytic leukemia (CLL) with 6 cycles of rituximab in combination with 6 or 26 cycles of ve … Pending
  2025-524283-38-00 5 Relapsed or refractory chronic lymphocytic leukemia
• Discontinuation of disease-modifying anti-rheumatic drugs (DMARDs) in rheumatoid arthritis patients also using TNF inhibitors Pending
  2026-525316-33-00 6 Rheumatoid arthritis
• Does progesterone luteal‑phase support increase live birth rates in couples with unexplained infertility assigned to expectant management? Pending
  2026-525747-33-00 6 unexplained subfertillity, infertillity
• A clinical trial of V940 with or without MK-3475A in people with non-small cell lung cancer (V940-014) Recruiting
  2025-522643-18-00 5 2026-06-16 Stage I NSCLC
• A Study of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50% Recruiting
  2025-523586-18-00 5 2026-06-11 Non-Small Cell Lung Cancer
• Crohn’s Head-to-Head Assessing Risankizumab Versus Guselkumab for One Year Recruiting
  2025-521590-13-00 5 2026-05-28 Moderately to Severely Active Crohn’s Disease
• A study to investigate the long-term safety, tolerability and efficacy of balinatunfib in participants with Crohn’s disease or ulcerative co … Recruiting
  2025-522511-42-00 4 2026-05-19 Crohn's disease
• An open-label extension (OLE) trial to evaluate long-term safety and tolerability of pelacarsen (TQJ230) Recruiting
  2024-519870-38-00 5 2026-05-11 Atherosclerotic cardiovascular disease (ASCVD)
• Adjuvant chemotherapy for prevention of recurrence in patients with detectable ctDNA after surgery in high-riskrectal cancer. Recruiting
  2024-517700-12-00 5 2025-12-10 Rectal cancer
• ASPIRING Recruiting
  2024-516188-10-00 6 2025-10-07 Intracerebral haemorrhage
• Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast C … Recruiting
  2024-515445-42-00 5 2025-03-24 Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast
• A multi-centred, partially randomised, patient-preference trial of radical surgery versus adjuvant chemoradiotherapy after local excision fo … Recruiting
  2024-517410-15-01 5 2025-01-14 Rectal cancer
• A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participant … Recruiting
  2023-505678-14-00 4 2024-08-19 Ulcerative Colitis
• A phase 2, multicenter, double-blind, two-arm study of subcutaneous RO7790121 for the treatment of subjects with moderate to severe active c … Recruiting
  2023-504265-23-00 4 2023-10-23 Crohn's disease
• This study is to find out the safety and effectiveness of Epcoritamab together with R-CHOP (rituximab, cyclophosphamide, doxorubicin HCL, vi … Recruiting
  2023-505277-32-00 5 2023-01-26 Diffuse Large B-Cell Lymphoma (DLBCL)
• A Phase 3 Study of I-DXd in Subjects with Relapsed SCLC Recruiting
  2023-509628-16-00 5 2026-05-07 Small Cell Lung Cancer (SCLC)
• A clinical trial of sacituzumab tirumotecan to treat urothelial cancer (MK-2870-031) Recruiting
  2024-520014-22-00 5 2026-04-22 Locally advanced/metastatic urothelial carcinoma

Showing 1–24 of 141 trials